FDA-compliant qualification of manufacturing plants for active pharmaceutical ingredients

被引:0
|
作者
Gengenbach, R [1 ]
机构
[1] Gempex GmbH, Mannheim, Germany
来源
PHARMAZEUTISCHE INDUSTRIE | 2003年 / 65卷 / 07期
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Qualification of pharmaceutical production plants nowadays being an essential quality assurance element is urgently required in the GMP (Good Manufacturing Practice) regulations. But nevertheless, many people still do not know exactly how to proceed, especially how to incorporate the various activities in the planning and building of intricate plants. The following article, after dealing briefly with regulatory requirements and explaining the most important terminology, depicts the individual steps such as DQ (Design Qualification), IQ (Installation Qualification), OQ (Operational Qualification), PQ (Performance Qualification), calibration, and maintenance in detail. The corresponding test items are listed and illustrated with the aid of specific examples. The article particularly focusses on the typical process performed for new plants, and shows a way to integrated plant qualification. Finally, qualification of already existing production plants is also described briefly.
引用
下载
收藏
页码:704 / 711
页数:8
相关论文
共 50 条
  • [41] Ionic Liquids as Active Pharmaceutical Ingredients
    Ferraz, Ricardo
    Branco, Luis C.
    Prudencio, Cristina
    Noronha, Joao Paulo
    Petrovski, Zeljko
    CHEMMEDCHEM, 2011, 6 (06) : 975 - 985
  • [42] Active pharmaceutical ingredients are big business
    Stoker, A
    TCE, 2002, (732): : 38 - 39
  • [43] Precision active pharmaceutical ingredients are the goal
    Miller, Andrew D.
    FUTURE MEDICINAL CHEMISTRY, 2016, 8 (11) : 1209 - 1238
  • [44] RAMAN ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS
    Mattley, Yvette
    CHEMICAL & ENGINEERING NEWS, 2014, : 31 - 31
  • [45] Active pharmaceutical ingredients and osteonecrosis of the jaw
    Orvosi Osztaly
    ORVOSI HETILAP, 2020, 161 (51) : 2176 - 2176
  • [46] Challenges in Nanogrinding of Active Pharmaceutical Ingredients
    Bitterlich, Andre
    Laabs, Christina
    Busmann, Eike
    Grandeury, Arnaud
    Juhnke, Michael
    Bunjes, Heike
    Kwade, Arno
    CHEMICAL ENGINEERING & TECHNOLOGY, 2014, 37 (05) : 840 - 846
  • [47] Asymmetric synthesis of active pharmaceutical ingredients
    Farina, Vittorio
    Reeves, Jonathan T.
    Senanayake, Chris H.
    Song, Jinhua J.
    CHEMICAL REVIEWS, 2006, 106 (07) : 2734 - 2793
  • [48] Why both LC-MS/MS and FDA-compliant validation are essential for accurate estrogen assays?
    Labrie, Fernand
    Ke, Yuyong
    Gonthier, Renaud
    Belanger, Alain
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2015, 149 : 89 - 91
  • [50] FDA to enhance pharmaceutical good manufacturing practices
    不详
    JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2002, 221 (09): : 1237 - 1237